Iterum Therapeutics PLC
NASDAQ:ITRM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.9099
2.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Iterum Therapeutics PLC
Iterum Therapeutics PLC
Net Issuance of Common Stock
Iterum Therapeutics PLC
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Net Issuance of Common Stock
$8m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Net Issuance of Common Stock
-$390.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
-47%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Net Issuance of Common Stock
$15.1m
|
CAGR 3-Years
224%
|
CAGR 5-Years
162%
|
CAGR 10-Years
-19%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Net Issuance of Common Stock
$15k
|
CAGR 3-Years
-86%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Net Issuance of Common Stock
-€1.4m
|
CAGR 3-Years
48%
|
CAGR 5-Years
46%
|
CAGR 10-Years
27%
|
|
Iterum Therapeutics PLC
Glance View
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.
See Also
What is Iterum Therapeutics PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
8m
USD
Based on the financial report for Jun 30, 2024, Iterum Therapeutics PLC's Net Issuance of Common Stock amounts to 8m USD.
What is Iterum Therapeutics PLC's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
41%
Over the last year, the Net Issuance of Common Stock growth was 817%. The average annual Net Issuance of Common Stock growth rates for Iterum Therapeutics PLC have been -58% over the past three years , 41% over the past five years .
You don't have any saved screeners yet
